BIOMAT Database Logo BIOMAT Database Logo

[Effective progestogen therapy of endometrial hyperplasia and adenocarcinoma by administration of a combined progestogen-estrogen preparation]. 1988

Y Miyawaki, and M Ueki, and O Sugimoto

UI MeSH Term Description Entries
D008656 Mestranol The 3-methyl ether of ETHINYL ESTRADIOL. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-, (17alpha)-,Ethinyl Estradiol 3-Methyl Ether,Ethinyl Estradiol 3 Methyl Ether
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009640 Norethindrone A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION. 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)-,Ethinylnortestosterone,Norethisterone,Norpregneninolone,Conceplan,Micronor,Monogest,Nor-QD,Norcolut,Norcolute,Norethindrone, (1 beta)-Isomer,Norlutin,Nor QD,NorQD
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004714 Endometrial Hyperplasia Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant. Atypical Endometrial Hyperplasia,Complex Endometrial Hyperplasia,Simple Endometrial Hyperplasia,Atypical Endometrial Hyperplasias,Complex Endometrial Hyperplasias,Endometrial Hyperplasia, Atypical,Endometrial Hyperplasia, Complex,Endometrial Hyperplasia, Simple,Endometrial Hyperplasias,Endometrial Hyperplasias, Atypical,Endometrial Hyperplasias, Complex,Endometrial Hyperplasias, Simple,Hyperplasia, Atypical Endometrial,Hyperplasia, Complex Endometrial,Hyperplasia, Endometrial,Hyperplasia, Simple Endometrial,Hyperplasias, Atypical Endometrial,Hyperplasias, Complex Endometrial,Hyperplasias, Endometrial,Hyperplasias, Simple Endometrial,Simple Endometrial Hyperplasias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Y Miyawaki, and M Ueki, and O Sugimoto
Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy.
January 2007, IARC monographs on the evaluation of carcinogenic risks to humans,
Y Miyawaki, and M Ueki, and O Sugimoto
Endometrial histology and parentereal estrogen-progestogen administration.
January 1969, Fertility and sterility,
Y Miyawaki, and M Ueki, and O Sugimoto
Endometrial response in estrogen replacement therapy quarterly combined with a progestogen.
May 1996, Maturitas,
Y Miyawaki, and M Ueki, and O Sugimoto
Treatment of premenopausal endometrial hyperplasia by a combination of a long-acting estrogen and a cyclic progestogen.
July 1973, Current therapeutic research, clinical and experimental,
Y Miyawaki, and M Ueki, and O Sugimoto
Artificial endometrial preparation for oocyte donation using synthetic estrogen and progestogen.
January 1998, Clinical and experimental obstetrics & gynecology,
Y Miyawaki, and M Ueki, and O Sugimoto
Estrogen replacement therapy and endometrial hyperplasia.
June 1996, JAMA,
Y Miyawaki, and M Ueki, and O Sugimoto
Estrogen replacement therapy and endometrial hyperplasia.
June 1996, JAMA,
Y Miyawaki, and M Ueki, and O Sugimoto
Bleeding patterns during continuous combined estrogen-progestogen therapy.
May 1991, American journal of obstetrics and gynecology,
Y Miyawaki, and M Ueki, and O Sugimoto
Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer.
December 2004, Breast (Edinburgh, Scotland),
Y Miyawaki, and M Ueki, and O Sugimoto
Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women.
December 1991, Obstetrics and gynecology,
Copied contents to your clipboard!